Tesamorelin: Research Applications

💊 HIV-Associated Lipodystrophy (FDA-registered)

The primary clinical application. Two pivotal Phase 3 trials (n=816) demonstrated 14–18% VAT reduction with 2 mg SC daily, with improvements in triglycerides (-12.3%), body image, and waist circumference. Reductions were maintained over 52 weeks but reversed upon discontinuation. [4] [10]

🫁 NAFLD / NASH

A 12-month RCT (n=61) in HIV-infected study subjects showed 37% hepatic fat reduction, with 35% achieving normal hepatic fat fraction (<5%). Critically, Tesamorelin prevented progression of liver fibrosis (10.5% vs 37.5% in placebo, P=0.04). [11]

🧠 Cognitive Function / MCI

In a blinded RCT (n=152) of healthy older adults and MCI study subjects, 1 mg daily for 20 weeks improved executive function (P=0.005) and global cognition (P=0.03), with IGF-1 increasing +117%. Mechanisms involve increased GABA and amyloid-beta modulation. [13]

🦴 Peripheral Nerve Regeneration

Preclinical GH models showed enhanced median nerve regeneration (axon density P<0.005, myelin thickness P<0.0001) and improved muscle re-innervation (38% vs 27.9%, P<0.02). Tesamorelin is identified as the optimal agent for human translation. [14]

❤️ Cardiovascular Risk Reduction

Reduces triglycerides and improves carotid intima-media thickness (cIMT). VAT reduction is theorized to lower atherosclerotic cardiovascular disease risk. Long-term cardiovascular outcomes remain under study. [15]

💪 Sarcopenia / Muscle Quality

Increases skeletal muscle density and area (particularly trunk region), independent of changes in muscle mass quantity. Replaces hypertrophic lipid-engorged fat cells with healthy tissue. [12]

🍬 Metabolic Syndrome / Type 2 Diabetes

A tolerability study in T2D study subjects (n=53) demonstrated neutral glucose effects — no significant changes in fasting glucose, HbA1c, or insulin response vs placebo. However, Phase 3 HIV data showed increased HbA1c risk (HR 3.3 vs placebo), warranting monitoring. [16]